Asset Details
Do you wish to reserve the book?
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
Do you wish to request the book?
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
2014
Overview
Sofosbuvir (Sovaldi
®
) is a nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitor that has pangenotypic antiviral activity and a high genetic barrier to resistance. This article reviews the clinical efficacy and tolerability of sofosbuvir in patients with chronic hepatitis C and summarizes its pharmacological properties. Interferon-free treatment with sofosbuvir plus ribavirin achieved high sustained virological response (SVR) rates in treatment-naïve and treatment-experienced patients with HCV genotype 2 or 3 infection, and also had efficacy in patients with HCV genotype 1 infection. Sofosbuvir plus ribavirin was also effective in patients co-infected with HCV and HIV, and sofosbuvir plus ribavirin administered prior to liver transplantation prevented recurrent HCV infection in the majority of patients who had HCV RNA levels below the limit of quantification at the time of transplantation. Sofosbuvir plus peginterferon-α-2a and ribavirin achieved high SVR rates in patients with HCV genotype 1 infection, and also appeared effective in patients with HCV genotype 4, 5 or 6 infection. Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C. The most commonly reported adverse events and laboratory abnormalities were consistent with those expected with ribavirin and peginterferon-α. In conclusion, sofosbuvir represents an important advance in the treatment of chronic hepatitis C.
Publisher
Springer International Publishing,Adis International,Springer Nature B.V
Subject
/ Antiviral Agents - pharmacology
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ Enzyme Inhibitors - pharmacology
/ Enzyme Inhibitors - therapeutic use
/ Hepatitis C, Chronic - drug therapy
/ Human immunodeficiency virus
/ Humans
/ Medicine
/ Mutation
/ Patients
/ Uridine Monophosphate - analogs & derivatives
/ Uridine Monophosphate - pharmacology
/ Uridine Monophosphate - therapeutic use
